Biogen earlier this month lost another legal battle over its patents for Tecfidera, its blockbuster multiple sclerosis drug, and will likely see multiple generic challengers in the months to come. The Delaware judge on Sept. 16 ruled in favor of Amneal Pharmaceuticals, which is developing its own generic version of Tecfidera, citing Mylan’s legal victory over Biogen in a West Virginia court in June. Mylan launched its own Tecfidera generic at the end of August. Tecfidera currently holds preferred status for 12% of all covered lives under the pharmacy benefit, growing to 54% with utilization management restrictions.

SOURCE: MMIT Analytics, as of 9/23/20